The effect of sepsis and septic shock on the viscoelastic properties of clot quality and mass using rotational thromboelastometry: A prospective observational study by Matthew, Lawrence et al.
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Journal of Critical Care
                                  
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa35869
_____________________________________________________________
 
Paper:
Davies, G., Lawrence, M., Pillai, S., Mills, G., Aubrey, R., Thomas, D., Williams, R., Morris, K. & Evans, P. (2017).
The effect of sepsis and septic shock on the viscoelastic properties of clot quality and mass using rotational
thromboelastometry: A prospective observational study. Journal of Critical Care
http://dx.doi.org/10.1016/j.jcrc.2017.09.183
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 Accepted Manuscript
The effect of sepsis and septic shock on the viscoelastic properties
of clot quality and mass using rotational thromboelastometry: A
prospective observational study
Gareth R. Davies, Matthew Lawrence, Suresh Pillai, Gavin M.
Mills, Robert Aubrey, Dafydd Thomas, Rhodri Williams, Keith
Morris, Phillip Adrian Evans
PII: S0883-9441(17)30767-0
DOI: doi:10.1016/j.jcrc.2017.09.183
Reference: YJCRC 52712
To appear in:
Please cite this article as: Gareth R. Davies, Matthew Lawrence, Suresh Pillai, Gavin M.
Mills, Robert Aubrey, Dafydd Thomas, Rhodri Williams, Keith Morris, Phillip Adrian
Evans , The effect of sepsis and septic shock on the viscoelastic properties of clot quality
and mass using rotational thromboelastometry: A prospective observational study. The
address for the corresponding author was captured as affiliation for all authors. Please
check if appropriate. Yjcrc(2017), doi:10.1016/j.jcrc.2017.09.183
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
1 
 
The effect of sepsis and septic shock on the viscoelastic properties of clot quality and mass using 
rotational thromboelastometry: a prospective observational study 
Authors: 
Gareth R Davies1,2 
Matthew Lawrence1,2 
Suresh Pillai3 
Gavin M Mills3 
Robert Aubrey3 
Dafydd Thomas4 
Rhodri Williams5 
Keith Morris6 
Phillip Adrian Evans1,2,3* 
 
Affiliated Institutions: 
 
1. Haemostasis Biomedical Research Unit (HBRU), Morriston Hospital, Swansea, UK. 
2. College of Medicine, Swansea University, Swansea, UK. 
3. Emergency Department, Morriston Hospital, ABM University Health Board, Swansea, UK. 
4. Cardiac Intensive Care Unit, Morriston Hospital, ABM University Health Board, Swansea, UK. 
5. College of Engineering, Swansea University, Swansea, UK. 
6. School of Applied Sciences, Cardiff Metropolitan University, Cardiff, UK. 
 
*corresponding author 
 e-mail: phillip.evans2@wales.nhs.uk 
 telephone: +44 1792 532419 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
2 
 
Conflicts of interest  
PAE and PRW have signed the International Committee of Medical Journal Editors (ICMJE) form for 
declaration of interest and have declared all conflict of interests. All other authors declare no 
competing conflicts of interest. 
 
Financial Disclosure Statement 
This study was funded by the National Institute for Social Care and Health Research (NISCHR) and 
was also part-funded by the European Social Fund (ESF) through the European Union’s Convergence 
programme administered by the Welsh Government. The funders had no role in study design, data 
collection and analysis, interpretation of data, or preparation of the manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
 
Abstract 
 
Purpose: The study purpose was to define changes in coagulation across the sepsis spectrum using 
rotational thromboelastometry (ROTEM). 
Methods: Sepsis patients were recruited on admission to the Emergency Department and Intensive 
Care Units of a large teaching hospital in Wales. ROTEM markers of clot development and fibrinolysis 
were determined, as well as standard coagulation markers. A healthy control group matched for age 
and gender was also recruited (n = 44).  
Results: 100 patients were recruited (50 sepsis, 20 severe sepsis and 30 septic shock). Maximum clot 
firmness was significantly higher in the sepsis (p < 0.001) and severe sepsis (p = 0.012) groups than 
the healthy control (71.6 ± 4.5 and 70.4 ± 4.1 vs 64.4 respectively). In septic shock there was 
prolonged clot development; however, maximum clot firmness remained normal. Fibrinolytic 
function was significantly impaired in septic shock, which was also significantly associated with 28-
day mortality (p < 0.001).  
Conclusions: ROTEM indicated significantly enhanced clot structural development in sepsis and 
severe sepsis, which could be indicative of a hypercoagulable phase. In septic shock, despite there 
being a prolongation of clotting pathways and impaired fibrinolysis, clot mass was comparably 
normal, suggestive of the development of a clot with healthy characteristics.  
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Introduction 
 
Sepsis is known to exert a complex effect on the coagulation system, globally affecting all aspects of 
clot formation, namely kinetic activity, clot development and fibrinolysis [1, 2]. It is critically 
important for the clinician to know how the underlying pathophysiological progression of sepsis 
affects the coagulation system in order to deliver and target appropriate therapy. Clinically, it is well 
recognised that the earlier phases of sepsis induce a hypercoagulable state, but in septic shock, 
there still remains uncertainty on how the underlying pathophysiology affects the coagulation 
profile, and eventual clot formation, particularly the effects on clot structural development.  
The hypercoagulable effect of sepsis leads to increased thromboembolic risk [3], but this is 
not detected by standard markers of coagulation [4]. Due to the limitations of conventional tests 
such as PT and aPTT, and the need for a dynamic, sensitive maker of coagulation, point of care tests 
of coagulation are increasingly utilised in the clinical setting [4]. Rotational Thromboelastometry 
(ROTEM) is a viscoelastic point of care test and provides bedside information on both clot structural 
development and fibrinolytic function. ROTEM can be performed using blood which has been 
activated through the extrinsic pathway (EXTEM test) or the intrinsic pathway (INTEM test). Whereas 
standard markers focus on the kinetics of coagulation, or concentration of individual components, 
ROTEM provides a global picture of the coagulation status of patients and their overall effect on clot 
outcome at point of care. ROTEM has the advantage that it is a point of care test, and not only gives 
the global effects of kinetic coagulation activity and fibrinolysis but also has the added advantage of 
being able to determine clot quality and mass. Therefore more recently studies have utilised either 
ROTEM or thromboelastography (TEG) as an improved measurement to quantify the effect of sepsis 
progression on coagulation in the various stages of severity [5–13]. 
These studies have utilised several parameters of the global test as a main outcome in 
treatment as well as assessing disease severity and outcome. One of the main parameters utilised to 
assess thrombogenicity has been maximum clot firmness (MCF) which is known to be a marker of 
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clot development and mass in sepsis and other disease states. Increased clot mass is indicative of a 
hypercoagulable state, whereas reduced clot mass and firmness is indicative of a hypocoagulable 
state [14] and is also associated with poor outcomes [7]. Although previous studies have looked at 
the different sepsis stages in isolation or comparatively, no previous study has assessed how 
progressive pathophysiological change across the sepsis spectrum affects the coagulation profile 
using ROTEM. In this prospective observational study ROTEM was used to determine global 
coagulation change across all stages of sepsis and compared to conventional markers of coagulation 
in patients presenting to the emergency department. All of these were compared against a healthy 
matched control independently.  
Some of the data related to the research in this manuscript was presented and published as 
an abstract in the International Symposium of Intensive Care and Emergency Medicine 2016 prior to 
the completion of this study [15, 16]. 
 
Material and Methods 
 
Ethical Approval 
Full ethical approval was given by the South West Wales Research Ethics Committee. Informed 2-
stage written consent was given by patients with capacity to do so. Assent was obtained from 
personal or legal representation in cases where capacity to give informed consent was lacking.  
 
Recruitment of Subjects with Sepsis 
Subjects that met sepsis criteria as outlined by the American College of Chest Physicians/Society of 
Critical Care Medicine in 1991 [17] were recruited to this study within 24 hours of admission. 
Patients on any medication likely to affect coagulation or those who had recently received 
anticoagulant therapy were excluded. Patients with any history of disease that affects the 
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coagulation profile (malignancy, renal failure, liver disease) were excluded. Patients that were 
deemed insensitive to include i.e. impending death were also excluded from the study. 
 At the time of recruitment, patients were categorised as sepsis, severe sepsis or septic 
shock. Categorisation was blinded, and carried out by an intensive care specialist independent of the 
study using the criteria established in 1991 [17]. All patients were defined at point of entry. 
 A group of healthy volunteers matched for age, gender and from a demographically similar 
population group was recruited as a healthy control. 
 
Blood Sampling 
Blood was sampled at the time of inclusion to the study, and the first 5mls of blood was always 
discarded. Blood was drawn into 3.2% sodium citrate vacutainers (Greiner Bio-One GmbH, Austria, 
REF: 454327) to assess standard coagulation markers (aPTT, PT, Fibrinogen) and ROTEM 
thromboelastometry. A further blood sample was drawn into EDTA vacutainers (Becton, Dickinson 
and Company, UK, REF: 367839) to assess platelet count. 
 
Laboratory Markers 
Standard coagulation markers (aPTT (instrinsic), PT (extrinsic) and fibrinogen) were determined using 
a Sysmex CA1500 automated analyser and platelet count was determined using a Sysmex XE 2100 
automated haematology analyser. All samples were analysed within 2 hours of collection. 
 
Rotational Thromboelastometry 
Thromboelastometry was performed using a ROTEM delta whole blood haemostasis system. Blood 
coagulation was assessed with ROTEM by both intrinsic (INTEM) and extrinsic (EXTEM) activation. 
Tests were carried out in accordance with the manufacturer’s recommendations using disposable 
cups and pins (Cup and pin pro, Tem Innovations GmbH, Martin-Kollar-Str, Germany, REF: 200011). 
The automated pipetting system was used to recalcify and activate the blood with the appropriate 
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reagents for each test. 20µl CaCl2 0.2M, STARTEM reagent (Tem innovations GmbH, Munich, 
Germany, REF: 503-10) and 20µl thromboplastin-phospholipid INTEM reagent (Tem innovations 
GmbH, Munich, Germany, REF: 503-02) were added to 300µL of blood for the INTEM test. 20µL CaCl2 
0.2M STARTEM reagent and 20µL tissue factor EXTEM reagent (Tem innovations GmbH, Munich, 
Germany, REF: 503-05) were added to 300µL blood for the EXTEM test. The Clotting Time (CT), 
Maximum Clot Firmness (MCF) and Lysis Index at 60 minutes (LI60) were recorded to assess the 
kinetic, structural and fibrinolytic aspects of clot development. 
 
Statistical Analysis 
All statistical analysis was carried out on IBM Statistical Package for Social Sciences (SPSS) for 
Windows, version 22.0 (Armonk, NY: IBM Corp.). Values are reported as mean and standard 
deviation or median and interquartile range where appropriate. Pearson’s chi-squared test was used 
to assess differences in the frequency distribution of nominal parameters across groups. Students T-
test was used to assess differences between two normally distributed groups whereas Kruskal-Wallis 
was used to determine differences between two non-normally distributed groups. One-way ANOVA 
was used to assess differences in normally distributed data between more than two groups, and 
Kruskal-Wallis was used to assess differences between more than two non-normally distributed 
groups. Data normality was assessed using Shapiro-Wilk test with an α value of 0.05. Bonferroni 
correction was used to assess multiple comparisons across groups. 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
Results 
 
Patient Characteristics 
100 sepsis patients in total were included in the study. This included 50 patients with sepsis, 20 with 
severe sepsis and 30 with septic shock. 44 healthy volunteers matched for gender and age were also 
recruited as a healthy control group. Patient groups were matched for age, gender and source of 
infection. SOFA score, hospital length of mortality and 28 day mortality were all significantly 
increased with increasing severity of group (p < 0.05). 
 
Changes in Standard Markers of Coagulation 
Standard kinetic markers (PT and aPTT) were normal early on in the sepsis and severe sepsis groups, 
but were significantly prolonged in septic shock, indicating hypocoagulability. Fibrinogen remained 
significantly elevated throughout all stages measured compared to the healthy control group, but 
this was more marked in the early stages of sepsis and severe sepsis in line with an underlying 
inflammatory effect indicative of a hypercoagulable phase (Table 1).  
 
Changes in Thromboelastometry Measurements (ROTEM) across the Sepsis Spectrum 
Baseline ROTEM measurements CT, MCF and LI60 are shown in Figure 1. A significant trend towards 
prolongation of EXTEM clotting time (CT) was observed with increasing severity of stage (p<0.001). 
Overall a hypercoagulable effect was observed in sepsis and severe sepsis, with a significant increase 
in the clot firmness and rate of formation. Furthermore, EXTEM clot formation time (CFT) was 
significantly shortened in the sepsis group compared to the healthy control (62.5 ± 15.3 vs 81.8 ± 
18.3 (p = 0.004)). In septic shock, ROTEM measurements indicated normal but delayed clot 
formation and significantly impaired fibrinolysis (p < 0.001). 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
Comparison between Survivors and non-Survivors at 28 Days 
All patients were followed up for all cause 28-day mortality. Characteristics of survivors and non-
survivors at 28 days are shown in Table 2. A significant trend towards hypocoagulability was 
observed in non-survivors compared to survivors.  Poor outcome was also associated with prolonged 
EXTEM CT and impaired fibrinolysis, as indicated by significantly increased LI60. Structural ROTEM 
parameters (MCF, α) were not significantly different in patients that did not survive 28 days. 
 
 
Discussion 
 
In this study for the first time several ROTEM parameters were determined against severity of stage 
of sepsis across the whole sepsis spectrum as a diagnostic test in the emergency setting at time of 
presentation. In this single study we demonstrated that in the earlier stages of sepsis progression 
(sepsis and severe sepsis), ROTEM was more sensitive in detecting a hypercoagulable phase when 
compared to standard markers of coagulation, indicating enhanced clot development in sepsis and 
severe sepsis when compared to the standard healthy control group and normal ROTEM ranges. 
These findings provide more evidence that a clear hypercoagulable state is associated with sepsis, 
with increased clot mass and viscoelasticity (MCF), as has been shown in previous studies [1, 18, 19]. 
Although there was no change in the initial time to clot formation (CT), the clot formation time (CFT) 
remained shortened in the earlier stages of sepsis indicating enhanced clot mass formation, 
suggesting altered mechanical clot properties. These findings were also reflected by a rapid increase 
in clot mass development, as measured by the α angle, and higher resultant MCF possibly indicative 
of the hypercoagulable phase and potential thromboembolic risk in the earlier stages of sepsis and 
severe sepsis as noted in previous studies [3]. In the later stage of septic shock both the CT and CFT 
were prolonged, indicative of a hypocoagulable phase. However, despite a prolongation of the time 
based ROTEM markers, both the alpha angle and MCF remained within the normal range in septic 
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shock, indicating normal clot development and mass as indicated by all structural markers of ROTEM 
thromboelastometry. This is indicative of a normally formed clot in septic shock, despite there being 
significant alterations in clotting time and fibrinolysis and is in contrast to recent studies which have 
specifically measured new markers of clot elasticity and strength [19]. These studies have shown 
that clot strength was significantly weakened when going from severe sepsis to the septic shock 
phase which was thought to be due to the effect on the mechanical strength by alteration of the 
cross-linked fabric leading to a looser, weaker clot. Furthermore, an increase in kinetic time in septic 
shock was mirrored by increases in the aPTT and PT, both of which were prolonged. Although 
ROTEM parameters in the earlier phases of sepsis indicated a hypercoagulable effect with increased 
clot mass, surprisingly ere was no change in clot formation or clot mass in the septic shock group, 
despite a profound effect of a decrease in the kinetic activity of clot formation. This may be partly 
explained by there being an elevated fibrinogen concentration and a normal platelet count.   
 Markers of fibrinolysis remained unchanged in the earlier phases of sepsis, but there was 
pronounced fibrinolytic activity and impaired fibrinolytic function in the septic shock group as 
measured by D-dimers and LI60 respectively. Although fibrinolytic function was impaired, D-dimer 
concentration indicated an increase in the fibrinolytic activity in septic shock. This suggests the 
ongoing intravascular fibrin formation (consumption), which could contribute to the impairment of 
the fibrinolytic and procoagulant systems. Previous studies have suggested that fibrinolysis is 
regulated in part by clot structure [20, 21], with denser, more elastic clots being more difficult to 
lyse. However, the results herein do not support this, as ROTEM indicated impaired fibrinolysis in 
weaker clots associated with septic shock. This again suggests the overall effects on coagulation 
could possibly be due to the overall consumption of procoagulant and fibrinolytic proteins that 
inevitably increases with increasing severity of sepsis, leading to an overall impairment of both clot 
development and breakdown.  
Previous studies have attempted to investigate this impairment of fibrinolysis in septic shock 
by measuring individual concentrations of fibrinolytic proteins in sepsis, and found that a reduced 
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plasminogen concentration was present in patients with severe sepsis/septic shock [2]. Furthermore, 
studies have shown there is a reduced tPA and PAI-1 concentration [22, 23, 24], which would 
suggest the fibrinolytic system is progressively overloaded as activation of the coagulation system is 
enhanced, which could help to explain the underlying development of DIC in sepsis. These 
mechanisms could help to explain the progressively increased risk of both bleeding and thrombosis 
that are observed with increasing severity of sepsis. 
In this study ROTEM gave some understanding and new information in profiling in the earlier 
stages of sepsis, indicating a hypercoagulable phase, but there was no consistent marker to indicate 
the progression from the early stages from sepsis to septic shock. Although ROTEM gave us some 
information regarding the kinetic information (time-based markers) and clot rigidity, ROTEM does 
not provide a measurement of elasticity, and even Newtonian fluids have been shown to provide 
substantial readings using thromboelastographic techniques [25]. 
 Although ROTEM has been utilised in the diagnosis of haemorrhage blood loss and 
component replacement in major haemorrhage associated with surgery [26–28] or trauma [29, 30], 
no studies have yet determined its usage as a marker of hyper and hypocoagulable states in patients 
attending the emergency department who were subsequently admitted to the ward or ICU. 
Although ROTEM determined a hypercoagulable phase indicative of an increased clot mass in sepsis, 
it did not differentiate between or show major change in clot mass in those patients that presented 
with septic shock. What remains uncertain is why ROTEM defines patients in septic shock still 
produce a normal profile of a clot. It may be that the measurement of clot development and 
strength is in mm, which is an arbitrary description, and not an exact scientific marker of elasticity or 
true clot strength.  
Further larger studies are required to ascertain the potential clinical utility of ROTEM within 
the emergency setting. Although ROTEM shows a normal MCF trace in septic shock, this may not 
reflect accurately the viscoelastic change, as determined previously. Further work is needed to 
determine the role that sepsis plays in altering the viscoelastic profile and its relationship to disease 
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severity and its effect on clot quality. There may very well be a discrepancy between clot mass, as 
measured by ROTEM and final clot strength in terms of its elastic mechanical properties, which 
warrants further studies to determine this relationship. 
 
Study Limitations 
As with other similar studies involving critically ill patients, this study has a number of limitations. It 
is difficult to account for comorbidities between the groups, and there could also be differences in 
concomitant medications. In an attempt to address this, strict inclusion/exclusion criteria were 
adopted. Furthermore, although several results were significant, this study was not powered for 
outcome. 
 
Conclusions 
ROTEM indicated enhanced clot mass and development in sepsis and severe sepsis, consistent with a 
hypercoagulable phase and increased thrombotic risk. However, in septic shock, despite 
prolongation of laboratory markers and clotting time, ROTEM indicated a normal clot mass and 
development consistent with a normocoagulable state. Despite the development of a normal clot 
mass in septic shock, ROTEM indicated an impairment of fibrinolysis, which could potentially lead to 
increased thrombotic risk, despite the lack of a perceived hypercoagulable state. 
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Tables 
 
Table 1: Changes in standard markers of coagulation across the sepsis spectrum. Standard 
laboratory markers of coagulation are shown for the different sepsis groups. Data presented as 
mean ± SD. Significance values indicated (One-way ANOVA). 
 
 Healthy Sepsis Severe Sepsis Septic Shock Significance 
Value 
PT (sec) 10.5 ± 0.6 11.0 ± 1.0 11.5 ± 1.2 13.3 ± 2.3 <0.001 
aPTT (sec) 25.4 ± 2.0 26.6 ± 3.1 29.1 ± 6.7 35.6 ± 8.9 <0.001 
Fibrinogen 
(g/L) 
3.1 ± 0.5 4.6 ± 0.6 4.5 ± 1.0  3.7 ± 1.6 <0.001 
Platelets 
(x109/L) 
255 ± 51 275 ± 96 262 ± 112 188 ± 120 0.001 
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Table 2: Comparison of ROTEM parameters in survivors and non-survivors. ROTEM parameters in 
sepsis patients that survived and did not survive 28 days are shown. Data presented as mean ± SD, 
median (IQR). Comparisons made using students t-test or Kruskal-Wallis test, with respective 
significant values indicated. 
 
ROTEM EXTEM 
Survived (n=83) Died (n=17) Significance Value 
CT (sec) 63.7 ± 14.7 82.8 ± 30.6 0.032 
MCF (mm) 69.6 ± 7.0 63.9 ±13.5 0.215 
LI60 (%) 94 (90.25, 96) 95.5 (92.5, 98)  <0.001 
ROTEM INTEM    
CT (sec) 162.0 ± 39.7 167.2 ± 50.5 0.623 
MCF (mm) 69.1 ± 7.2 64.8 ± 14.3 0.405 
LI60 (%) 94 (90, 96) 96 (94.75, 98) <0.001 
 
 
Figure Legend. 
 
 
Figure 1: Changes in the different ROTEM parameters across the sepsis spectrum. ROTEM markers 
of coagulation across the sepsis and in the healthy control group are shown. Data presented as box 
plots (median and IQR) with whiskers representing the range. Healthy reference ranges as 
recommended by ROTEM are also shown on each graph respectively. Significant differences 
between groups assessed using Kruskal-Wallis test with multiple comparisons (Bonferroni 
correction). 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
20 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
 
 
 
 
 
  
p < 0.05 
p < 0.001 
p < 0.001 
p < 0.001 p < 0.05 
p < 0.001 p < 0.001 
p < 0.001 p < 0.05 
p < 0.01 
p < 0.001 
p < 0.001 
p < 0.001 
p < 0.01 
p < 0.001 
p < 0.001 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
21 
 
Highlights 
 ROTEM was used to assess clot development across the sepsis spectrum. 
 Clot development was significantly enhanced in sepsis and severe sepsis. 
 Clot development was normal in septic shock. 
 Fibrinolysis was significantly impaired in septic shock. 
 Impaired fibrinolysis was also significantly associated with 28 day mortality. 
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